Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 30, 2008

Vermillion and Quest Prolong Diagnostic Collaboration

  • Vermillion and Quest Diagnostics will extend their diagnostic development alliance until October 2009. This enables the companies to continue work on the development and commercialization of two tests, OVA1™ and Vasclir™.

    Vermillion reports that it began its partnership with Quest in 2005 to develop and commercialize diagnostic tests. The OVA1 test is intended to identify women with ovarian tumors that are at high risk of being malignant. Vermillion has a pending a 510(k) application before the FDA. Vasclir is a blood test being designed to identify an individual’s risk of developing peripheral artery disease.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »